Biogen Idec Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

291.48USD
4:00pm EDT
Price Change (% chg)

$5.99 (+2.10%)
Prev Close
$285.49
Open
$290.28
Day's High
$294.00
Day's Low
$284.54
Volume
610,586
Avg. Vol
640,949
52-wk High
$358.72
52-wk Low
$194.68

BIIB.OQ

Chart for BIIB.OQ

About

Biogen Idec Inc. (Biogen Idec) is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. In September 2011, the Company... (more)

Overall

Beta: 1.21
Market Cap (Mil.): $67,488.10
Shares Outstanding (Mil.): 236.39
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 36.53 32.56 32.65
EPS (TTM): 7.82 -- --
ROI: 20.24 19.75 19.01
ROE: 23.90 20.45 19.78
Search Stocks

Biotech stocks rout beginning to reveal pockets of value

NEW YORK - Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

1:05am EDT

Biogen's blood disorder drug succeeds in late-stage trial

- Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.

10 Apr 2014

UPDATE 1-Biogen's blood disorder drug succeeds in late-stage trial

April 10 - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in treating children with hemophilia in a late-stage trial.

10 Apr 2014

Biogen's blood disorder drug succeeds in late-stage trial

April 10 - Biogen Idec Inc and Swedish Orphan Biovitrum said their experimental blood disorder drug was effective in maintaining low bleeding rates in children in a late-stage trial.

10 Apr 2014

U.S. FDA approves Biogen's hemophilia B drug Alprolix

- Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.

28 Mar 2014

UPDATE 1-U.S. FDA approves Biogen's hemophilia B drug Alprolix

March 28 - Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.

28 Mar 2014

U.S. FDA approves Biogen's hemophilia B drug Alprolix

March 28 - Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday.

28 Mar 2014

Biogen Idec wins Canadian approval for hemophilia drug Alprolix

- Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix.

21 Mar 2014

UPDATE 1-Biogen Idec wins Canadian approval for hemophilia drug Alprolix

March 21 - Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix.

21 Mar 2014

Biogen Idec wins Canadian approval for hemophilia drug Alprolix

March 21 - Biogen Idec Inc said on Friday it had won Canadian approval for its long-lasting hemophilia B drug Alprolix.

21 Mar 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $98.75 -0.45
Pfizer Inc. (PFE.N) $30.09 +0.20
Novartis AG (NOVN.VX) CHF74.35 +0.80
Merck & Co., Inc. (MRK.N) $56.26 +0.21
Roche Holding Ltd. (ROG.VX) CHF254.20 +0.90
Bayer AG (BAYGn.DE) €92.93 +1.42
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.77 +0.75
GlaxoSmithKline plc (GSK.L) 1,563.50p +16.50
Teva Pharmaceutical Industries Limited (TEVA.TA) 17,450.00₪ -10.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks